

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 22, 2025

RWPE-1

RRID:CVCL_3791

Type: Cell Line

Proper Citation

(ATCC Cat# CRL-3607, RRID:CVCL_3791)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3791

Proper Citation: (ATCC Cat# CRL-3607, RRID:CVCL_3791)

Sex: Male

Defining Citation: [PMID:8977636](#), [PMID:9214605](#), [PMID:9214606](#), [PMID:20215515](#), [PMID:22275356](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:30305041](#), [PMID:30787054](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: DNA methylation analysis., Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Group: Patented cell line.

Category: Transformed cell line

Name: RWPE-1

Synonyms: RWPE1

Cross References: BTO:BTO_0003709, CLO:CLO_0008905, EFO:EFO_0002323, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-3610, ATCC:CRL-3607, ATCC:CRL-11609, BCRJ:0389, BioSample:SAMN03470832, BioSample:SAMN05292437, BioSample:SAMN07709991, BioSample:SAMN07709992, BioSample:SAMN07709993, BioSample:SAMN07709994, BioSample:SAMN07709995, BioSample:SAMN07709996, BioSample:SAMN07709997, cancercellines:CVCL_3791, CCRID:3101HUMGNHu37, CCRID:3101HUMSCSP5025, CCRID:4201HUM-CCTCC00178, CCTCC:GDC0178, Cell_Model_Passport:SIDM00020, ChEMBL-Cells:ChEMBL4295468, ChEMBL-Targets:ChEMBL4296492, CLS:305217, EGA:EGAS00001000978, ENCODE:ENCBS124FCL, ENCODE:ENCBS192LWI, ENCODE:ENCBS263AAA, ENCODE:ENCBS875FPF, GEO:GSM827387, GEO:GSM1008595, GEO:GSM1374860,

GEO:GSM1670396, IGRhCellID:RWPE1, Lonza:870, PharmacDB:RWPE1_1336_2019, Progenetix:CVCL_3791, PubChem_Cell_line:CVCL_3791, Wikidata:Q54951497

ID: CVCL_3791

Vendor: ATCC

Catalog Number: CRL-3607

Record Creation Time: 20250131T202506+0000

Record Last Update: 20250131T204407+0000

Ratings and Alerts

No rating or validation information has been found for RWPE-1.

No alerts have been found for RWPE-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 703 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Awad D, et al. (2024) Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. *Cancer research*, 84(5), 703.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. *Cancer cell*.

Walker L, et al. (2024) Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer. *Molecular cancer research : MCR*, 22(12), 1128.

Da Silva AJ, et al. (2024) Proteomic profiling identifies a direct interaction between heat shock transcription factor 2 and the focal adhesion adapter talin-1. *The FEBS journal*, 291(21), 4830.

Tian Y, et al. (2024) Identify Regulatory eQTLs by Multiome Sequencing in Prostate Single Cells. *bioRxiv : the preprint server for biology*.

Lee J, et al. (2024) Investigating miR-6880-5p in extracellular vesicle from plasma as a prognostic biomarker in endocrine therapy-treated castration-resistant prostate cancer. *BMC*

cancer, 24(1), 909.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. *Cancer cell*, 42(10), 1676.

Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. *EBioMedicine*, 105, 105212.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. *iScience*, 27(3), 108794.

Li S, et al. (2024) NOSTRIN is involved in benign prostatic hyperplasia via inhibition of proliferation, oxidative stress, and inflammation in prostate epithelial cells. *Translational andrology and urology*, 13(9), 2055.

Xia W, et al. (2024) Anoikis in prostate cancer bone metastasis gene signatures and therapeutic implications. *Frontiers in oncology*, 14, 1446894.

Luo Y, et al. (2024) Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance. *International journal of cancer*, 155(4), 742.

Liu Z, et al. (2024) YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia. *iScience*, 27(3), 109125.

Awah CU, et al. (2024) The Engineered Drug 3'UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer. *Cancers*, 16(15).

Silva F, et al. (2023) Image-Guided Nanodelivery of Pt(IV) Prodrugs to GRP-Receptor Positive Tumors. *Nanotheranostics*, 7(1), 22.

Yang L, et al. (2023) A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance. *Scientific reports*, 13(1), 5779.

Li C, et al. (2023) The m6A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma. *Frontiers in immunology*, 14, 1086907.

Wu Z, et al. (2023) TPM2 attenuates progression of prostate cancer by blocking PDLIM7-mediated nuclear translocation of YAP1. *Cell & bioscience*, 13(1), 39.

Park JY, et al. (2023) Panax ginseng C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced side effects. *Frontiers in pharmacology*, 14, 1039622.

Järemo H, et al. (2023) Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328. *Cancers*, 15(9).